Overview

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Capecitabine
Sunitinib